Come up with a name for your new list and we'll add to it:
RedoxTherapies was acquired by
Juno Therapeutics on July 14, 2016.
RedoxTherapies is a company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibit…